Pacific Biosciences of California, Inc. (PACB)
Levi & Korsinsky Announces an Investigation on Behalf of Pacific Biosciences of California, Inc. (PACB) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Shareholders Can Join In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Did Pacific Biosciences of California, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PACB
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Shareholders Eligible To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Pacific Biosciences of California, Inc.(PACB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Investors Able To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California, Inc. (PACB) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Levi & Korsinsky Reminds Pacific Biosciences of California, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - PACB
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
PACB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacific Biosciences of California, Inc.
NEW YORK, NY / ACCESSWIRE / August 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
